Amyloid fibril formation is suppressed in microgravity.

Amyloid fibrils Amyloidosis Aβ, amyloid β Aβ42 DMSO, dimethyl sulfoxide FSB, 1-fluoro-2,5-bis[(E)-3-carboxy-4-hydroxystyryl]benzene Insulin Microgravity PBS, phosphate-buffered saline TTR TTR, transthyretin TTRwt, wild-type transthyretin ThT, thioflavin T

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 29 07 2020
revised: 27 11 2020
accepted: 09 12 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

In the future, humans may live in space because of global pollution and weather fluctuations. In microgravity, convection does not occur, which may change the amyloidogenicity of proteins. However, the effect of gravity on amyloid fibril formation is unclear and remains to be elucidated. Here, we analyzed the effect of microgravity on amyloid fibril formation of amyloidogenic proteins including insulin, amyloid β

Identifiants

pubmed: 33364446
doi: 10.1016/j.bbrep.2020.100875
pii: S2405-5808(20)30185-0
pmc: PMC7750487
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100875

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest relevant to the content of this article.

Références

Stem Cell Res Ther. 2013 Apr 01;4(2):35
pubmed: 23548163
Orphanet J Rare Dis. 2013 Feb 20;8:31
pubmed: 23425518
Biochemistry. 1996 May 21;35(20):6470-82
pubmed: 8639594
PLoS One. 2009 Jul 23;4(7):e6343
pubmed: 19626124
Amyloid. 2018 Dec;25(4):215-219
pubmed: 30614283
Diabetes. 2019 Mar;68(3):609-616
pubmed: 30552107
Transl Neurodegener. 2014 Sep 13;3:19
pubmed: 25228988
Alzheimers Res Ther. 2019 Oct 18;11(1):86
pubmed: 31627745
Annu Rev Biochem. 2017 Jun 20;86:27-68
pubmed: 28498720
NPJ Microgravity. 2018 May 23;4:11
pubmed: 29845109
J Biol Chem. 2019 Jul 19;294(29):11259-11275
pubmed: 31167790
Mod Pathol. 2011 Dec;24(12):1533-44
pubmed: 21822203
J Pathol. 2009 Dec;219(4):481-90
pubmed: 19790249
Neurosci Res. 2006 Dec;56(4):441-9
pubmed: 17028027
Annu Rev Med. 2003;54:245-56
pubmed: 12471177
J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050
pubmed: 30336828

Auteurs

Hiroaki Matsushita (H)

Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch Sasebo, Nagasaki, 859-3298, Japan.

Aito Isoguchi (A)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Masamitsu Okada (M)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Teruaki Masuda (T)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Yohei Misumi (Y)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Yuko Ichiki (Y)

Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch Sasebo, Nagasaki, 859-3298, Japan.

Mitsuharu Ueda (M)

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Yukio Ando (Y)

Department of Amyloidosis Research, Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch Sasebo, Nagasaki, 859-3298, Japan.
Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-0811, Japan.

Classifications MeSH